PE20050773A1 - Compuestos de quinolina sustituidos - Google Patents
Compuestos de quinolina sustituidosInfo
- Publication number
- PE20050773A1 PE20050773A1 PE2005000125A PE2005000125A PE20050773A1 PE 20050773 A1 PE20050773 A1 PE 20050773A1 PE 2005000125 A PE2005000125 A PE 2005000125A PE 2005000125 A PE2005000125 A PE 2005000125A PE 20050773 A1 PE20050773 A1 PE 20050773A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- quinoline
- phenyl
- integer number
- biphenyl
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title abstract 4
- -1 QUINOLINE COMPOUND Chemical group 0.000 abstract 5
- 239000002253 acid Substances 0.000 abstract 2
- KIYRSYYOVDHSPG-UHFFFAOYSA-N 2-amino-2-phenylacetamide Chemical compound NC(=O)C(N)C1=CC=CC=C1 KIYRSYYOVDHSPG-UHFFFAOYSA-N 0.000 abstract 1
- 101710095342 Apolipoprotein B Proteins 0.000 abstract 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 101000977048 Streptomyces cinnamonensis Uncharacterized protein in mutB 3'region Proteins 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 230000003228 microsomal effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE QUINOLINA SUSTITUIDOS DE FORMULA (I) DONDE R1 ES UN GRUPO DE FORMULA R1a Y ESTA UNIDO A LA POSICION 2 o 3 DEL GRUPO QUINOLINA DE FORMULA I DONDE m ES UN NUMERO ENTERO DE 0 A 2, n ES UN NUMERO ENTERO DE 0 A 4, p ES UN NUMERO ENTERO DE 0 A 5, q ES UN NUMERO ENTERO DE 0 3, R ES UN ENLACE O UN NUMERO ENTERO DE 1 A 3; X ES -N O -C (Ra)- DONDE Ra ES H O R9 ; X1 ES -N- O -C (Rb )- DONDE Rb ES H O R7; R2 , R7 , R8 Y R9 SE SELECCIONAN DE HALO, -OH, -CN, ALQUILO (C1-C4), ALCOXI (C1-C4)-, R5 Y R10 SE SELECCIONAN CADA DE H, ALQUILO (C1-C4), ALQUILO (C1-C4) SUSTITUIDO CON HALO; R6 ES ALQUILO (C1-C10), PIRIDILO, FENILO O FENIL-ALQUILO (C1-C6)-, ALQUENILO (C2-C10); Y ES H, ALQUILO C1-C8, CICLOALQUILO C3-C7-ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS (CARBAMOIL-FENIL-METIL)-AMIDA DEL ACIDO (S)-2-[(4'-TRIFLUOROMETIL-BIFENIL-2-CARBONIL)-AMINO]-QUINOLINA-6-CARBOXILICO, (METILCARBAMOIL-FENIL-METIL)-AMIDA DEL ACIDO (S)-2-[(4'-TRIFLUOROMETIL-BIFENIL-2-CARBONIL)-AMINO]-QUINOLINA-6-CARBOXILICO, [FENIL-(2,2,2-TRIFLUORO-ETILCARBAMOIL)METIL]-AMIDA DEL ACIDO 2-[(4'-TRIFLUOROMETIL-BIFENIL-2-CARBONIL)-AMINO]-QUINOLINA-6-CARBOXILICO, ENTRE OTROS. LOS COMPUESTOS DE QUINOLINA SON INHIBIDORES DE LA PROTEINA DE TRANSFERENCIA DE TRIGLICERIDOS MICROSOMAL (MTP) Y/O DE LA SECRECION DE LA APOLIPOPROTEINA B (APO B) UTILES EN EL CONTROL DEL PESO Y TRATAMIENTO DE LA OBESIDAD
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54167804P | 2004-02-04 | 2004-02-04 | |
| US63376304P | 2004-12-06 | 2004-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050773A1 true PE20050773A1 (es) | 2005-10-26 |
Family
ID=34890449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000125A PE20050773A1 (es) | 2004-02-04 | 2005-02-02 | Compuestos de quinolina sustituidos |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US7468378B2 (es) |
| EP (1) | EP1716137A1 (es) |
| JP (1) | JP2007520543A (es) |
| KR (1) | KR100799802B1 (es) |
| AP (1) | AP2006003685A0 (es) |
| AR (1) | AR047529A1 (es) |
| AU (1) | AU2005214159A1 (es) |
| BR (1) | BRPI0507462A (es) |
| CA (1) | CA2555133A1 (es) |
| CO (1) | CO5700721A2 (es) |
| CR (1) | CR8544A (es) |
| EA (1) | EA010369B1 (es) |
| EC (1) | ECSP066717A (es) |
| GE (1) | GEP20084360B (es) |
| IL (2) | IL176715A0 (es) |
| MA (1) | MA28347A1 (es) |
| NL (1) | NL1028192C2 (es) |
| NO (1) | NO20063928L (es) |
| OA (1) | OA13365A (es) |
| PA (1) | PA8623001A1 (es) |
| PE (1) | PE20050773A1 (es) |
| SV (1) | SV2007002007A (es) |
| TW (2) | TWI306454B (es) |
| UY (1) | UY28734A1 (es) |
| WO (1) | WO2005080373A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1682537E (pt) | 2003-11-05 | 2012-06-20 | Sarcode Bioscience Inc | Moduladores de adesão celular |
| WO2005080373A1 (en) * | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US20070203139A1 (en) * | 2004-04-14 | 2007-08-30 | Astrazeneca Ab | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| EA024768B1 (ru) | 2005-04-19 | 2016-10-31 | Сюрфэйс Лоджикс, Инк. | Ингибиторы белка микросомального транспорта триглицеридов и секреции апо-в |
| EP2222631B1 (en) * | 2006-10-23 | 2011-08-17 | Pfizer Inc. | Substituted phenylmethyl bicyclocarboxyamide compounds |
| JP2010509392A (ja) | 2006-11-13 | 2010-03-25 | ファイザー・プロダクツ・インク | ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用 |
| WO2008097471A1 (en) * | 2007-02-02 | 2008-08-14 | Shivvers Steve D | High efficiency drier with multi stage heating and drying zones |
| WO2008100423A1 (en) * | 2007-02-09 | 2008-08-21 | Sirtris Pharmaceuticals, Inc. | Gut microsomal triglyceride transport protein inhibitors |
| WO2009052182A1 (en) | 2007-10-15 | 2009-04-23 | Jbs United, Inc. | Method for increasing performance of offspring |
| WO2009014674A1 (en) * | 2007-07-23 | 2009-01-29 | Sirtris Pharmaceuticals, Inc. | Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors |
| US20090155176A1 (en) | 2007-10-19 | 2009-06-18 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
| WO2010018547A1 (en) * | 2008-08-13 | 2010-02-18 | Pfizer Inc. | Aminoquinoline compounds |
| MX2013015058A (es) | 2011-06-24 | 2014-01-20 | Amgen Inc | Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos. |
| MY157429A (en) | 2011-06-24 | 2016-06-15 | Amgen Inc | Trpm8 antagonists and their use in treatments |
| KR101979042B1 (ko) * | 2011-08-04 | 2019-05-15 | 어레이 바이오파마 인크. | 세린/트레오닌 키나제 억제제로서의 퀴나졸린 화합물 |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| WO2015121877A2 (en) * | 2014-02-17 | 2015-08-20 | Hetero Research Foundation | Polymorphs of lomitapide and its salts |
| MX2017004543A (es) | 2014-10-06 | 2017-10-04 | Vertex Pharma | Moduladores de regulador de conductancia transmembranal de fibrosis quística. |
| US10138206B2 (en) | 2014-10-09 | 2018-11-27 | Glenmark Pharmaceuticals Limited | Amorphous form of lomitapide mesylate |
| ES2946970T3 (es) | 2016-03-31 | 2023-07-28 | Vertex Pharma | Regulador de conductancia transmembrana de moduladores de fibrosis quística |
| UA124708C2 (uk) | 2016-09-30 | 2021-11-03 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятор муковісцидозного регулятора трансмембранної провідності, фармацевтичні композиції, способи лікування та спосіб отримання модулятора |
| MD3551622T2 (ro) | 2016-12-09 | 2021-03-31 | Vertex Pharma | Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului |
| MA54105A (fr) | 2017-06-08 | 2021-09-15 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| EP3640242B1 (en) * | 2017-06-16 | 2023-04-19 | Hitgen Ltd. | Rock-inhibiting compound and uses thereof |
| WO2019018395A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | METHODS OF TREATING CYSTIC FIBROSIS |
| WO2019028228A1 (en) | 2017-08-02 | 2019-02-07 | Vertex Pharmaceuticals Incorporated | PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS |
| AU2018351533B2 (en) | 2017-10-19 | 2023-02-02 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2819039A1 (de) | 1978-04-29 | 1979-11-08 | Bayer Ag | Leimungsmittel fuer papier |
| IL65219A (en) | 1981-03-11 | 1986-03-31 | Wellcome Found | Pharmaceutical compositions containing diarylcarboxylic acids,some new such(substituted phenyl)benzoic and naphthoic acids,and their preparation |
| JP2527107B2 (ja) | 1991-04-16 | 1996-08-21 | 日本新薬株式会社 | 固体分散体の製造方法 |
| CA2091102C (en) | 1992-03-06 | 2009-05-26 | John R. Ii Wetterau | Microsomal triglyceride transfer protein |
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| DE69531458T2 (de) | 1994-05-27 | 2004-08-05 | Glaxosmithkline S.P.A. | Chinolinderivate als tachykinin nk3 rezeptor antagonisten |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| DE19519245C2 (de) * | 1995-04-14 | 2003-04-30 | Boehringer Ingelheim Kg | Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| WO1996040640A1 (en) | 1995-06-07 | 1996-12-19 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
| DK0832069T3 (da) | 1995-06-07 | 2003-04-22 | Pfizer | Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) |
| US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| DE69738949D1 (de) * | 1996-05-20 | 2008-10-09 | Darwin Discovery Ltd | Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren |
| IL121203A (en) | 1996-07-01 | 2001-04-30 | Lilly Co Eli | 1, 2, 3, 4-tetrahydroisoquinidines, process for their preparation and pharmaceutical compositions containing the same for treating hyperglycemia and hyperlipidemia |
| KR100217618B1 (ko) * | 1996-12-12 | 1999-09-01 | 정몽규 | 와셔액 분사위치 조절 장치 |
| WO1998027979A1 (en) | 1996-12-20 | 1998-07-02 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of microsomal triglyceride transfer protein and method |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US5968950A (en) | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
| PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| AP1201A (en) | 1997-09-17 | 2003-09-01 | Smithkline Beecham Corp | Method for the synthesis of quinoline derivatives. |
| RU2220960C2 (ru) * | 1997-12-22 | 2004-01-10 | Фармация Энд Апджон Компани | 4-гидрокси-3-хинолинкарбоксамиды и гидразиды, фармацевтическая композиция и способ лечения на их основе |
| CO5090829A1 (es) | 1998-07-21 | 2001-10-30 | Novartis Ag | Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b. |
| CO5271688A1 (es) | 1999-11-10 | 2003-04-30 | Pfizer Prod Inc | Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales |
| CA2325358C (en) | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
| US20020032238A1 (en) * | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
| US6417367B1 (en) * | 2000-08-11 | 2002-07-09 | Pfizer Inc. | Methods of making quinoline amides |
| JP2004510763A (ja) | 2000-10-05 | 2004-04-08 | 藤沢薬品工業株式会社 | アポｂ分泌阻害剤としてのベンズアミド化合物 |
| NZ528752A (en) | 2001-06-28 | 2006-06-30 | Pfizer Prod Inc | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (APO B) secretion |
| WO2003035624A1 (en) * | 2001-10-25 | 2003-05-01 | Takeda Chemical Industries, Ltd. | Quinoline compound |
| CA2468989A1 (en) * | 2001-12-07 | 2003-06-19 | Daniel M. Schwartz | Treatment for age-related macular degeneration |
| US20030162788A1 (en) * | 2002-01-10 | 2003-08-28 | Boehringer Ingelheim Pharma Kg | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals |
| NZ531890A (en) | 2002-02-28 | 2006-02-24 | Japan Tobacco Inc | Ester compound and medicinal use thereof |
| EP1578725A1 (en) * | 2002-12-20 | 2005-09-28 | Pfizer Products Inc. | Microsomal triglyceride transfer protein inhibitors |
| EP1581499A1 (en) * | 2002-12-20 | 2005-10-05 | Pfizer Products Inc. | Microsomal triglyceride transfer protein inhibitors |
| WO2005080373A1 (en) * | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
-
2005
- 2005-01-24 WO PCT/IB2005/000167 patent/WO2005080373A1/en not_active Ceased
- 2005-01-24 AU AU2005214159A patent/AU2005214159A1/en not_active Abandoned
- 2005-01-24 GE GEAP20059563A patent/GEP20084360B/en unknown
- 2005-01-24 EP EP05702327A patent/EP1716137A1/en not_active Withdrawn
- 2005-01-24 EA EA200601239A patent/EA010369B1/ru not_active IP Right Cessation
- 2005-01-24 CA CA002555133A patent/CA2555133A1/en not_active Abandoned
- 2005-01-24 OA OA1200600247A patent/OA13365A/en unknown
- 2005-01-24 JP JP2006551942A patent/JP2007520543A/ja active Pending
- 2005-01-24 BR BRPI0507462-2A patent/BRPI0507462A/pt not_active IP Right Cessation
- 2005-01-24 KR KR1020067015770A patent/KR100799802B1/ko not_active Expired - Fee Related
- 2005-01-24 AP AP2006003685A patent/AP2006003685A0/xx unknown
- 2005-02-02 AR ARP050100394A patent/AR047529A1/es not_active Application Discontinuation
- 2005-02-02 UY UY28734A patent/UY28734A1/es unknown
- 2005-02-02 PE PE2005000125A patent/PE20050773A1/es not_active Application Discontinuation
- 2005-02-03 US US11/049,852 patent/US7468378B2/en not_active Expired - Fee Related
- 2005-02-03 TW TW094103301A patent/TWI306454B/zh not_active IP Right Cessation
- 2005-02-03 TW TW097141214A patent/TW200906800A/zh unknown
- 2005-02-04 SV SV2005002007A patent/SV2007002007A/es not_active Application Discontinuation
- 2005-02-04 PA PA20058623001A patent/PA8623001A1/es unknown
- 2005-02-04 NL NL1028192A patent/NL1028192C2/nl not_active IP Right Cessation
-
2006
- 2006-06-15 US US11/424,488 patent/US7368573B2/en not_active Expired - Fee Related
- 2006-07-05 IL IL176715A patent/IL176715A0/en unknown
- 2006-07-21 EC EC2006006717A patent/ECSP066717A/es unknown
- 2006-07-28 CO CO06074303A patent/CO5700721A2/es not_active Application Discontinuation
- 2006-08-03 CR CR8544A patent/CR8544A/es not_active Application Discontinuation
- 2006-08-04 MA MA29241A patent/MA28347A1/fr unknown
- 2006-09-01 NO NO20063928A patent/NO20063928L/no not_active Application Discontinuation
- 2006-10-30 US US11/554,351 patent/US7393958B2/en not_active Expired - Fee Related
-
2010
- 2010-10-27 IL IL208963A patent/IL208963A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050773A1 (es) | Compuestos de quinolina sustituidos | |
| PE20030135A1 (es) | Derivados indol sustituido con triamida como inhibidores de la secrecion de mtp | |
| PE20120655A1 (es) | Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map) | |
| PE20120334A1 (es) | COMPUESTOS HETEROCICLICOS INHIBIDORES DE LAS PROTEINAS ANTI-APOPTOTICAS Bcl2 | |
| PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| EA200870358A1 (ru) | 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1 | |
| CO6160323A2 (es) | Derivados de quinazolinona 5-sustituidos como agentes antitumorales | |
| AR052156A1 (es) | Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos | |
| PE20141375A1 (es) | Activadores de glucoquinasa | |
| PE20110398A1 (es) | BENZAMIDAS CON ACTIVIDAD SOBRE LA ENZIMA p38 MAP-QUINASA | |
| CO6160235A2 (es) | Isoxazolinas insecticidas | |
| PE20070078A1 (es) | Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa | |
| AR064355A1 (es) | Herbicidas derivados de isoxazol | |
| PE20090641A1 (es) | Amidas heterociclicas | |
| PE20080688A1 (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de trpv1 y su preparacion | |
| EA200602066A1 (ru) | Кристаллические полиморфные формы n-[8(2-гидроксибензоил)амино]каприлата натрия | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| PE20120024A1 (es) | DERIVADOS DE LA PIRIDINA SUSTITUIDO CON ANILLO HETEROCICLICO Y GRUPO y- GLUTAMINICO, Y AGENTES ANTIFUNGALES QUE LOS CONTIENEN | |
| DK1716152T3 (da) | Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser | |
| PE20071254A1 (es) | Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion | |
| PE20050460A1 (es) | COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO) | |
| MX2009012377A (es) | Compuestos de arilamida pirimidona. | |
| PE20060727A1 (es) | Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) | |
| MX2009012383A (es) | Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |